Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept.
We present a case where etanercept--a soluble tumor necrosis factor receptor-Fc fusion protein-was safe and effective in treating the painful skin lesions of a 24-year-old patient with hidradenitis suppurativa, resulting in an improvement in quality of life.
Henderson
Robert L
RL
Shelby Dermatology, PC, Alabaster, AL 35007, USA. rlhenderson@shelbydermatology.com
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D055502:Secondary Prevention; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept